Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganoderma lucidum spore polysaccharide is a bioactive carbohydrate extract derived from the spores of the medicinal fungus *Ganoderma lucidum* (Reishi). Developed primarily by Nanjing Zhongke Group, it functions as an immunomodulator that enhances the host's immune response by activating natural killer (NK) cells, macrophages, and T-lymphocytes. It also promotes the secretion of essential cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-gamma). In clinical settings, particularly in China, it is utilized as an adjuvant therapy for cancer patients to mitigate the adverse effects of chemotherapy, such as fatigue and anorexia, and to improve overall quality of life. Research suggests it may also possess direct anti-tumor properties by inhibiting cancer cell proliferation and migration through various signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ganoderma lucidum spore polysaccharide.